Australia Pharmaceutical Cdmo Market Size & Outlook
Australia pharmaceutical cdmo market, 2018-2030 (US$M)
Related Markets
Australia pharmaceutical cdmo market highlights
- The Australia pharmaceutical cdmo market generated a revenue of USD 2,923.2 million in 2023 and is expected to reach USD 4,976.1 million by 2030.
- The Australia market is expected to grow at a CAGR of 7.9% from 2024 to 2030.
- In terms of segment, api was the largest revenue generating product in 2023.
- API is the most lucrative product segment registering the fastest growth during the forecast period.
Pharmaceutical cdmo market data book summary
| Market revenue in 2023 | USD 2,923.2 million |
| Market revenue in 2030 | USD 4,976.1 million |
| Growth rate | 7.9% (CAGR from 2023 to 2030) |
| Largest segment | Api |
| Fastest growing segment | API |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | API, Drug Product |
| Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
Other key industry trends
- In terms of revenue, Australia accounted for 2.0% of the global pharmaceutical cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China pharmaceutical cdmo market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 30,630.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pharmaceutical CDMO Market Scope
Pharmaceutical CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia pharmaceutical cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical cdmo market will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 81.42% in 2023. Horizon Databook has segmented the Australia pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2018 to 2030.
Australia has one of the best healthcare systems in the world. The increasing awareness about the need for early detection of lifestyle and chronic diseases is boosting the market in the country. Like other governments, the Australian government also initiated schemes to provide medicines at subsidized rates.
For instance, as per the Pharmaceutical Benefits Scheme (PBS), medicines are available for all eligible patients at a subsidized cost. These factors are expected to improve & promote the demand for pharmaceutical manufacturing, thus boosting the demand for pharmaceutical CDMO services in the country.
Furthermore, the adoption of advanced manufacturing technologies and processes can enhance efficiency, reduce costs, and improve the overall quality of pharmaceutical CDMO. This is expected to support the demand for pharmaceutical CDMOs in Australia.
Reasons to subscribe to Australia pharmaceutical cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia pharmaceutical cdmo market databook
-
Our clientele includes a mix of pharmaceutical cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia pharmaceutical cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Australia pharmaceutical cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia pharmaceutical cdmo market size, by product, 2018-2030 (US$M)
Australia Pharmaceutical CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
